Table 1:

 

ACIP Recommendations for Influenza Vaccination (1)

 

            Persons greater than age 50

Children age 6 months 18 years

 

Persons with any one of the following

 

            Underlying medical conditions

            Pregnant

            Healthcare workers

            Household contacts of high risk patients

 

  

Table 2:  Influenza Vaccines Available in the United States, 2008-2009.

 

Vaccine

Trade Name

Manufacturer

Approved Age

Mercury Content

Route

 

 

 

 

μg per 0.5 ml

 

LA/IV

FluMist

Medimmune

2-49 yr (healthy persons)

 

0

intranasal

TIV

Fluzone

Sanofi Pasteur

> 6 mo

25 (multidose vial); 0 (single-dose prefilled syringe)

intramuscular

TIV

Fluvirin

Novartis Vaccines

> 4 yr

25.4 (multidose vial); 0 (single-dose prefilled syringe)

intramuscular

TIV

Fluarix

GlaxoSmithKline

> 18 yr

<1.0 (single-dose prefilled syringe)

intramuscular

TIV

FluLaval

GlaxoSmithKline

> 18 yr

25 (multidose vial)

intramuscular

TIV

Afluria

CSL Biotherapies

> 18 yr

25 (multidose vial); 0 (single-dose prefilled syringe)

intramuscular

Reprinted from Glezen WP, NEJM 2008 (5)

 

  Table 3:  Antiviral Agents for Treatment of and Prophylaxis against Influenza

 

Drug

Formulation

Adult Dose

Common Side Effects

 

 

Treatment

Prophylaxis

 

Oseltamivir (Tamiflu, Roche)

75-mg capsule

1 capsule twice a day for 5 days

1 capsule/day

Nausea, vomiting

Zanamivir (Relenza, GlaxoSmithKline)

5 mg per inhalation (Diskhaler)

2 inhalations twice a day for 5 days

2 inhalations/day

Bronchospasm

Amantadine (Symmetrel, Endo Pharmaceuticals)

100-mg tablet

1 tablet twice a day for 3-5 days

1 table/day

CNS effects: seizures, insomnia

Rimantadine (Flumadine, Forst Laboratories)

100-mg tablet

1 tablet twice a day for 5 days

1 tablet/day

_

Ribavirin (Virazole, Valeant Pharmaceuticals)

60 mg/ml in reservoir

Aerosol for 2 hr every 8 hr for 5 days or as indicated

Not applicable

_

  Reprinted from Glezen WP, NEJM 2008 (5)